These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31816043)

  • 41. Astrocyte molecular signatures in Huntington's disease.
    Diaz-Castro B; Gangwani MR; Yu X; Coppola G; Khakh BS
    Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP.
    Hong Y; Zhao T; Li XJ; Li S
    J Neurosci; 2016 Aug; 36(34):8790-801. PubMed ID: 27559163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Altered reactivity of central amygdala to GABA
    Lamirault C; Yu-Taeger L; Doyère V; Riess O; Nguyen HP; El Massioui N
    Neuropharmacology; 2017 Sep; 123():136-147. PubMed ID: 28587900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
    Im W; Ban JJ; Chung JY; Lee ST; Chu K; Kim M
    Sci Rep; 2015 Nov; 5():16887. PubMed ID: 26586297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
    Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
    Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted Genetic Reduction of Mutant Huntingtin Lessens Cardiac Pathology in the BACHD Mouse Model of Huntington's Disease.
    Park S; Luk SHC; Bains RS; Whittaker DS; Chiem E; Jordan MC; Roos KP; Ghiani CA; Colwell CS
    Front Cardiovasc Med; 2021; 8():810810. PubMed ID: 35004919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Olfactory bulb atrophy and caspase activation observed in the BACHD rat models of Huntington disease.
    Lessard-Beaudoin M; Yu-Taeger L; Laroche M; Singer E; Riess O; Nguyen HHP; Graham RK
    Neurobiol Dis; 2019 May; 125():219-231. PubMed ID: 30738141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysregulation of gene expression in the striatum of BACHD rats expressing full-length mutant huntingtin and associated abnormalities on molecular and protein levels.
    Yu-Taeger L; Bonin M; Stricker-Shaver J; Riess O; Nguyen HHP
    Neuropharmacology; 2017 May; 117():260-272. PubMed ID: 28153533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease.
    Molero AE; Arteaga-Bracho EE; Chen CH; Gulinello M; Winchester ML; Pichamoorthy N; Gokhan S; Khodakhah K; Mehler MF
    Proc Natl Acad Sci U S A; 2016 May; 113(20):5736-41. PubMed ID: 27140644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cell-cell junction remodeling in the heart: possible role in cardiac conduction system function and arrhythmias?
    Mezzano V; Sheikh F
    Life Sci; 2012 Feb; 90(9-10):313-21. PubMed ID: 22227473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations.
    Cepeda C; Oikonomou KD; Cummings D; Barry J; Yazon VW; Chen DT; Asai J; Williams CK; Vinters HV
    J Neurosci Res; 2019 Dec; 97(12):1624-1635. PubMed ID: 31353533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease.
    Hult Lundh S; Nilsson N; Soylu R; Kirik D; Petersén Å
    Hum Mol Genet; 2013 Sep; 22(17):3485-97. PubMed ID: 23697793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
    Stanek LM; Bu J; Shihabuddin LS
    Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.